BIOM-14 Patterns, risk factors and management of CD19-directed Chimeric Antigen Receptor T-cell therapy failure in CNS lymphoma
Abstract
CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) demonstrates encouraging activity in CNS lymphoma (CNSL), yet most patients ultimately develop progressive disease (PD). Predictors, radiographic patterns, and optimal salvage strategies after CD19-CAR failure remain poorly defined. We retrospectively characterized clinical and radiographic features of CD19-CAR failure in CNSL treated at Massachusetts General Hospital. PD patterns were classified as local (involving or adjacent to baseline lesions) or distant. CNS progression-free survival from CD19-CAR infusion (CNS-PFS1) and from first subsequent progression (CNS-PFS2) were analyzed. CD19-CAR achieved a 60% overall response rate in 60 patients with active recurrent CNSL, including 45% complete and 15% partial responses. Median CNS-PFS1 was 4 months. Radiographic PD occurred in 36 patients and was local in 23.3%, combined local/distant in 16.7%, and distant in 20%. Progression patterns correlated with initial CD19-CAR response: distant relapse predominantly followed complete response, whereas local PD was associated with primary refractory disease. Lesions with peripheral contrast enhancement (pCE) at CD19-CAR infusion correlated with refractory disease, while leptomeningeal disease (LMD) was associated with recurrence following complete response. On multivariable Cox regression, pCE (hazard ratio [HR] 2.75, 95% confidence interval [CI] 1.08-6.68; p = 0.03) and LMD (HR 2.72, 95% CI 1.20-6.25; p = 0.02) were independently associated with shorter CNS-PFS1. At progression, peripheral CD19+ B-cell aplasia was present in 93% of patients, suggesting systemic CD19-CAR persistence despite CNS progression. Median CNS-PFS2 after CD19-CAR failure was 1 month. Immune checkpoint inhibition and lenalidomide-based combinations including rituximab or tafasitamab demonstrated encouraging salvage activity. This study identifies radiographic risk factors and progression patterns associated with CD19-CAR failure in CNSL. Outcomes after progression remain poor, supporting prospective evaluation of rational salvage immunotherapeutic strategies.